Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2015 March;57(1) > Panminerva Medica 2015 March;57(1):1-13

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  TARGETING CARDIAC ISSUES


Panminerva Medica 2015 March;57(1):1-13

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Bioresorbable scaffolds: focus on vascular response and long-term safety

Scalone G., Brugaletta S., Gomez O., Otsuki S., Sabate M.

Thorax Institute, Department of Cardiology, IDIBAPS: Institut d’Investigacions Biomediques Agust Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain


PDF  


Bioresorbable vascular scaffolds (BVS) are considered the fourth revolution in Interventional Cardiology, thus promising to address some of the pending issues with current-generation drug eluting stents (DES). Notably, most of the potential advantages of BVS over other current devices are due to a peculiar vascular response, called “vascular restoration therapy”. The emerging data from real-world expanded use registries suggest that BVS use is feasible in a wide variety of patients (from low- to high- risk), and lesions (from simplex to complex). However, few safety concerns with currently available BVS have arised from initial experiences all over the word. Data from ongoing large-scale randomized controlled trials will be able to demonstrate whether BVS improve patient early and long-term outcomes compared to best-in-class DES.

top of page

Publication History

Cite this article as

Corresponding author e-mail

masabate@clinic.ub.es.